Tuesday Jan 27, 2026
Tuesday Jan 27, 2026
Tuesday, 27 January 2026 03:09 - - {{hitsCtrl.values.hits}}
Yaden Laboratories Ltd., 100% Sri Lankan-owned and the nation’s leading pharmaceutical manufacturer, has announced a major expansion of its manufacturing footprint by initiating a new state-of-the-art project. This was formalised through the signing of a strategic agreement with the Board of Investment (BOI) of Sri Lanka to establish Unit II within the Katunayake Export Processing Zone (EPZ).
CMD Shashimal Dissanayake said: “Our signing with the BOI reinforces Yaden’s mission to strengthen Sri Lanka’s healthcare self-sufficiency. By investing in Unit II, we are not just expanding our capacity, but ensuring that our nation has consistent access to life-saving medicines produced right here at home”.
Expanding the footprint of excellence
This new venture follows the resounding success of Unit I, Yaden’s existing sterile formulation finished dosage facility. Since commencing operations in October 2022 with an initial investment of $ 16 million, Unit I has supplied 6.5 million units of liquid injectables to the local market and achieved a historic milestone in September 2025 as the first-ever company in Sri Lanka to export sterile formulations, already supplying essential medicines to countries including Zambia, Somalia, and Cambodia.
Yaden Laboratories...
The expansion: Unit II
The estimated investment value for the proposed expansion project is $ 25 million, marking a historic milestone as the first facility in Sri Lanka set to be equipped to handle
lyophilized vials along with liquid injectables as dosage forms. This dedicated Unit II facility will utilize modern technology fully compliant with local and international GMP standards to export as well.
Official agreement signing
The agreement was formalised on Friday, 23 January 2026 between the BOI Investment
Promotion team and Yaden’s leadership, including CMD Shashimal Dissanayake, Director Parana Hewage Sriyani Chandraseeli, CEO Prakash Babu, CFC Gayan Rajapakse, and Head of Legal Thilini Gunawardana.
